Log in

ASX:ACRAcrux Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/13/2020)
Today's Range
Now: A$0.14
50-Day Range
MA: A$0.13
52-Week Range
Now: A$0.14
Volume4,000 shs
Average Volume188,859 shs
Market Capitalization$22.74 million
P/E RatioN/A
Dividend YieldN/A
Acrux Limited, together with its subsidiaries, develops and commercializes specialty and generic topical pharmaceuticals in Australia, Switzerland, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was founded in 1998 and is based in West Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.65 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales$3.39 million
Cash FlowA$0.09 per share
Book ValueA$0.09 per share



Market Cap$22.74 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ACR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACR and its competitors with MarketBeat's FREE daily newsletter.

Acrux (ASX:ACR) Frequently Asked Questions

How has Acrux's stock been impacted by COVID-19 (Coronavirus)?

Acrux's stock was trading at A$0.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACR shares have increased by 3.8% and is now trading at A$0.14. View which stocks have been most impacted by Coronavirus.

How were Acrux's earnings last quarter?

Acrux Limited (ASX:ACR) announced its quarterly earnings results on Thursday, February, 21st. The company reported ($0.02) earnings per share for the quarter. View Acrux's earnings history.

Has Acrux been receiving favorable news coverage?

News stories about ACR stock have been trending negative recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acrux earned a news impact score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Acrux.

Who are some of Acrux's key competitors?

What other stocks do shareholders of Acrux own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acrux investors own include Australia and New Zealand Banking Group (ANZ), Lynas (LYC), Altium (ALU), Atlas Iron (AGO), Hugo Boss (BOSS), BHP Group (BHP), Beacon Roofing Supply (BECN), Billabong (BBG), Abraxas Petroleum (AXAS) and Ausdrill (ASL).

Who are Acrux's key executives?

Acrux's management team includes the following people:
  • Mr. Michael Kotsanis B.Sc., BSc, GradDipBus, MBus, CEO, MD & Exec. Director (Age 53)
  • Mr. Tim Bateman, CFO & Company Sec.
  • Ms. Felicia Colagrande BSc (Hons), MBA, Product Devel. & Technical Affairs Director
  • Mr. Charles O'Sullivan B. Pharm, Grad. Dip. Epi. & Biostats, Portfolio Director

What is Acrux's stock symbol?

Acrux trades on the ASX under the ticker symbol "ACR."

What is Acrux's stock price today?

One share of ACR stock can currently be purchased for approximately A$0.14.

How big of a company is Acrux?

Acrux has a market capitalization of $22.74 million and generates $3.39 million in revenue each year.

What is Acrux's official website?

The official website for Acrux is www.acrux.com.au.

How can I contact Acrux?

Acrux's mailing address is 103-113 Stanley St, MELBOURNE, VIC 3003, Australia. The company can be reached via phone at +61-3-83790100.

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.